Skip to content

Cumberland Pharmaceuticals Inc.: 10-Q filed 2025-11-07

What Cumberland Pharmaceuticals Inc. reported in its quarterly report filed 2025-11-07 (fiscal Q3 2025): 45 published measures, 129 facts as tagged in accession 0001087294-25-000020.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-07
Fiscal period
fiscal Q3 2025
Accession
0001087294-25-000020 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cumberland Pharmaceuticals Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3065,898,560USD
At 2024-12-3175,583,410USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-3040,097,856USD
At 2024-12-3153,037,433USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-3026,119,854USD
At 2024-12-3122,853,494USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-3015,196,745USD
At 2024-12-3117,964,184USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,940,764USD92
2025-01-01 to 2025-09-30-1,424,436USD273
2024-07-01 to 2024-09-30-1,544,081USD92
2024-01-01 to 2024-09-30-4,575,956USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-304,929,498USD273
2024-01-01 to 2024-09-30-2,516,804USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-09-3097,904USD273
2024-01-01 to 2024-09-3064,178USD274

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-07-01 to 2025-09-308,292,362USD92
2025-01-01 to 2025-09-3030,842,780USD273
2024-07-01 to 2024-09-309,085,826USD92
2024-01-01 to 2024-09-3027,432,376USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-6,063,778USD273
2024-01-01 to 2024-09-301,575,283USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-1,633,159USD273
2024-01-01 to 2024-09-3084,651USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-25,392,367USD
At 2024-12-31-23,967,931USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3014,958,534shares92
2025-01-01 to 2025-09-3014,953,944shares273
2024-07-01 to 2024-09-3014,052,754shares92
2024-01-01 to 2024-09-3014,089,496shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3014,958,534shares92
2025-01-01 to 2025-09-3014,953,944shares273
2024-07-01 to 2024-09-3014,052,754shares92
2024-01-01 to 2024-09-3014,089,496shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.13USD/shares92
2025-01-01 to 2025-09-30-0.1USD/shares273
2024-07-01 to 2024-09-30-0.11USD/shares92
2024-01-01 to 2024-09-30-0.32USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.13USD/shares92
2025-01-01 to 2025-09-30-0.1USD/shares273
2024-07-01 to 2024-09-30-0.11USD/shares92
2024-01-01 to 2024-09-30-0.32USD/shares274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-07-01 to 2025-09-305,670USD92
2025-01-01 to 2025-09-3017,011USD273
2024-07-01 to 2024-09-3011,442USD92
2024-01-01 to 2024-09-3034,327USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-30293,375USD
At 2024-12-31277,365USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-30236,160USD273
2024-01-01 to 2024-09-30227,083USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,965,260USD92
2025-01-01 to 2025-09-30-1,420,791USD273
2024-07-01 to 2024-09-30-1,694,432USD92
2024-01-01 to 2024-09-30-4,590,370USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3029,939,448USD
At 2024-12-3136,452,158USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2025-07-01 to 2025-09-30109,699USD92
2025-01-01 to 2025-09-30383,048USD273
2024-07-01 to 2024-09-30137,374USD92
2024-01-01 to 2024-09-30382,247USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-3024,309,969USD
At 2024-12-3131,621,729USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-3013,832,497USD
At 2024-12-3113,914,266USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2025-09-30914,000USD
At 2024-12-31914,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-09-3015,010,795USD
At 2024-12-3117,973,449USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-3010,430,602USD
At 2024-12-3111,701,466USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2025-01-01 to 2025-09-30263,478USD273
2024-01-01 to 2024-09-30480,666USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-09-302,934,723USD
At 2024-12-313,999,995USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,253,367USD92
2025-01-01 to 2025-09-304,016,842USD273
2024-07-01 to 2024-09-301,306,095USD92
2024-01-01 to 2024-09-303,523,535USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3014,956,627shares
At 2024-12-3113,952,624shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-3015,196,745USD
At 2024-12-3117,964,184USD
At 2024-09-3017,464,754USD
At 2023-12-3118,321,624USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2025-09-3025,800,704USD
At 2025-06-3027,678,927USD
At 2025-03-3128,340,619USD
At 2024-12-3122,545,977USD
At 2024-09-3024,469,392USD
At 2024-06-3026,032,184USD
At 2024-03-3127,189,552USD
At 2023-12-3129,259,869USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-307,570,452USD
At 2024-12-316,176,923USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-304,997,213USD
At 2024-12-315,296,247USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-302,986,628USD
At 2024-12-312,784,016USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-305,951,386USD
At 2024-12-316,299,795USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-301,377,378USD
At 2024-12-312,786,513USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,943,376USD92
2025-01-01 to 2025-09-30-1,419,058USD273
2024-07-01 to 2024-09-30-1,525,527USD92
2024-01-01 to 2024-09-30-4,507,751USD274

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,949,046USD92
2025-01-01 to 2025-09-30-1,436,069USD273
2025-04-01 to 2025-06-30-735,207USD91
2025-01-01 to 2025-03-311,248,184USD90
2024-07-01 to 2024-09-30-1,536,969USD92
2024-01-01 to 2024-09-30-4,542,078USD274
2024-04-01 to 2024-06-30-1,102,637USD91
2024-01-01 to 2024-03-31-1,902,472USD91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,572,066USD92
2025-01-01 to 2025-09-307,909,996USD273
2024-07-01 to 2024-09-302,675,380USD92
2024-01-01 to 2024-09-307,800,435USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-01-01 to 2025-09-303,103,306USD273
2024-01-01 to 2024-09-303,406,166USD274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,009,598USD92
2025-01-01 to 2025-09-303,021,412USD273
2024-07-01 to 2024-09-301,078,290USD92
2024-01-01 to 2024-09-303,288,808USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-03-314,715,950USD90

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-1,270,864USD273
2024-01-01 to 2024-09-301,552,449USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-2,448,605USD273
2024-01-01 to 2024-09-30-1,072,295USD274

Inspect the source

Entity
Cumberland Pharmaceuticals Inc. / CIK 0001087294
Captured
2026-09-20T05:21:29.619Z
SEC response SHA-256
b37ed2fef35db1cde0c40b2233eb97cf370fc96d41a5c7d61b6a5a76a296e4a0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001087294.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))